Description

Clinician Update on Human Cases of H5N1 and Influenza A Virus Surveillance   Overview The Centers for Disease Control and Prevention (CDC) continues to emphasize the importance of ongoing surveillance to detect human infections of avian influenza A(H5N1) virus. Since 2022 to mid-April 2025, 71 human cases of avian influenza A(H5) were identified in the United States, including 70 occurring during 2024 and 2025. Most human cases reported unprotected workplaces exposures, such as contact with avian influenza A(H5N1) virus-infected dairy cows or poultry without using recommended personal protective equipment; however, two cases involved exposure to backyard poultry or wild birds, and the source of the exposure in three cases could not be determined. Given the pandemic risk posed by novel influenza A viruses, including avian influenza A(H5N1) viruses, healthcare providers should remain alert to the possibility of human infections with novel influenza A viruses, particularly if a patient has relevant exposure history.    During this COCA Call, presenters will give updates on the current situation with human cases of influenza A(H5) in the United States and CDC's surveillance and monitoring efforts for influenza A virus infections among people in the United States. The discussion will emphasize what is expected of state and local partners and clinicians during the summer months when seasonal influenza virus circulation is typically low.    If you are unable to attend the live session of this COCA Call, the fully closed-captioned video and written transcript will be available on the COCA Call webpage approximately one week after the live session.   The slide set will be available on the day of the call on the COCA Call webpage under Call Materials.   Free Continuing Education (CE) will be offered for this COCA Call. Registration is not required.   Date: Tuesday, May 6, 2025   Time: 2:00 PM – 3:00 PM ET Webinar Link: https://www.zoomgov.com/j/1610226268   Webinar ID: 161 022 6268  Passcode: 340155 Telephone: +1 646 828 7666    One-tap Mobile:  +16692545252,,1610226268#,,,,*340155#    Activity-specific Objectives At the conclusion of the session, the participant will be able to accomplish the following: Provide an update on human infections with avian influenza A(H5N1) virus in the United States. Discuss CDC's surveillance and monitoring efforts for avian influenza A(H5N1) virus infections in people. Outline the public health implications of avian influenza A(H5N1) virus in animals and the importance of early detection of human infections and control measures.  Describe expectations for summertime influenza surveillance activities in the United States, including collecting and testing recommended clinical specimens for influenza viruses, subtyping influenza A positive specimens, and submitting influenza A(H5) positive specimens to CDC.    COCA Call Objectives Cite background information on the topic covered during the presentation. Discuss CDC’s role in the topic covered during the presentation. Describe the topic’s implications for clinicians. Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats. Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.   Presenters Tim Uyeki, MD, MPH, MPP Chief Medical Officer Influenza Division  National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention   Alicia Budd, MPH Team Lead, National Surveillance and Outbreak Response Team Epidemiology and Prevention Branch Influenza Division National Center for Immunization and Respiratory Disease Centers for Disease Control and Prevention       Instructions for Obtaining Continuing Education To receive continuing education (CE) for WC4520R-050625—Clinician Update on Human Cases of H5N1 and Influenza A Virus Surveillance, please visit CDC TRAIN and search for the course in the Course Catalog using WC4520R-050625. Follow the steps below by June 9, 2025. The registration code is COCA050625.   To receive continuing education (CE) for WD4520R-050625—Clinician Update on Human Cases of H5N1 and Influenza A Virus Surveillance, please visit CDC TRAIN and search for the course in the Course Catalog using WD4520R-050625.    Follow the steps below between June 10, 2025, and June 10, 2027:   1. Register for and complete the course. 2. Pass the post-assessment at 75%. 3. Complete the evaluation. 4. Visit Your Learning to access your certificates and transcript.   Accreditation Statement In support of improving patient care, The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.     CME: The Centers for Disease Control and Prevention designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.   AAPA CME: Credit Designation Statement – Live The Centers for Disease Control and Prevention has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.   CNE: The Centers for Disease Control and Prevention designates this activity for 1 nursing contact hours.   CPE: The Centers for Disease Control and Prevention designated this Knowledge-based event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is JA4008229-0000-25-026-L04-P and enduring is JA4008229-0000-25-027-H04-P.   CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program.   CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 1 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 1. Continuing Competency credits available are 1. CDC provider number 98614.   AAVSB/RACE: This program has been submitted (but not yet approved) for 1 hours of continuing education credit in jurisdictions which recognize AAVSB RACE approval; however, participants should be aware that some boards have limitations on the number of hours accepted in certain categories or restrictions on certain methods of delivery of continuing education.   For Certified Public Health Professionals (CPH): The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credits for this program.   DISCLOSURE: In compliance with continuing education requirements, all planners and presenters/moderators must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.   CDC, our planners, and presenters/moderators wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.   Content will not include any discussion of the unlabeled use of a product or a product under investigational use, with the exception of Dr. Tim Uyeki's discussion of the use of FDA-approved antivirals for treatment of influenza in outpatients for use in hospitalized patients and higher dosing for treatment and post-exposure prophylaxis.    CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity. The Office of Emergency Risk Communication in the Office of Communications is responsible for the management of all COCA Products.  For information about this update or other clinical issues, or to send your feedback, please contact us at coca@cdc.gov Clinician Outreach and Communication Activity—resources for healthcare providers COCA RSS Feed—subscribe to be notified of conference calls, updates, and CDC guidance for health providers Crisis & Emergency Risk Communication Training—training program that draws from lessons learned during public health emergencies, and incorporates best practices from the fields of risk and crisis communication Health Alert Network—CDC's primary method of sharing cleared information about urgent public health incidents with public information officers; federal, state, territorial, and local public health practitioners; clinicians; and public health laboratories

CDC and HHS logos are the exclusive property of the Department of Health and Human Services and may not be used for any purpose without prior express written permission. Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

 

Links to non-federal organizations are provided solely as a service to our users. Links do not constitute an endorsement of any organization by CDC or the federal government, and none should be inferred. CDC is not responsible for the content of the individual organizations.